Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection. Pharmacokinetics of insulin glargine is characterized by biotransformation into metabolites M1 and M2 that transforms the B chain of glargine s...
Enregistré dans:
Auteurs principaux: | Vadim Valer'evich Klimontov, Natalya Evgen'evna Myakina |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/68134155cb3a4de7b6012ca1ba4f09a4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
par: L. N. Shitov, et autres
Publié: (2019) -
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
par: Alexander Y. Mayorov, et autres
Publié: (2020) -
On the safety of insulin Glargine
par: Ivan Ivanovich Dedov, et autres
Publié: (2009) -
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
par: Lau IT, et autres
Publié: (2017) -
Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
par: Elena Valer'evna Biryukova, et autres
Publié: (2012)